{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:45:27Z","timestamp":1790783127434,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.revmed.2023.11.006","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:44:02Z","timestamp":1707813842000},"page":"126-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Des taux \u00e9lev\u00e9s d\u2019auto-anticorps anti-topo-isom\u00e9rase-1\u00a0sont associ\u00e9s \u00e0 l\u2019extension de la fibrose cutan\u00e9e et \u00e0 la progression vasculaire chez les patients atteints de scl\u00e9rodermie syst\u00e9mique"],"prefix":"10.1016","volume":"45","author":[{"given":"C.","family":"Dol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Granel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Resseguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kaplanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schleinitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lafforgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Benyamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.revmed.2023.11.006_bib0120","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013\u00a0classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den\u00a0Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2023.11.006_bib0125","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/diagnostics12051067","article-title":"Autoantibodies versus skin fibrosis extent in systemic sclerosis: a case-control study of inverted phenotypes","volume":"12","author":"Tieu","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"10.1016\/j.revmed.2023.11.006_bib0130","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.revmed.2023.11.006_bib0135","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.006_bib0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.revmed.2023.11.006_bib0145","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","article-title":"Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis","volume":"73","author":"Minier","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.revmed.2023.11.006_bib0150","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.41814","article-title":"Anticentromere antibody levels and isotypes and the development of systemic sclerosis","volume":"73","author":"van\u00a0Leeuwen","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.revmed.2023.11.006_bib0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3899\/jrheum.180503","article-title":"Presence of anti-topoisomerase I antibody alone may not be sufficient for the diagnosis of systemic sclerosis","volume":"46","author":"Tebo","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.11.006_bib0160","doi-asserted-by":"crossref","first-page":"987","DOI":"10.5604\/17322693.1117543","article-title":"Serological profile of patients with systemic sclerosis","volume":"68","author":"Wielosz","year":"2014","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"3","key":"10.1016\/j.revmed.2023.11.006_bib0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis-specific antibodies: novel and classical biomarkers","volume":"64","author":"Cavazzana","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.006_bib0170","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2622","article-title":"Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.revmed.2023.11.006_bib0175","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.revmed.2023.11.006_bib0180","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","article-title":"Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database","volume":"75","author":"Wirz","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2023.11.006_bib0185","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1093\/rheumatology\/keac047","article-title":"Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis","volume":"61","author":"Tsuji","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.006_bib0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum anti-nuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.revmed.2023.11.006_bib0195","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.22747","article-title":"Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody","volume":"56","author":"Perera","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.revmed.2023.11.006_bib0200","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2023.11.006_bib0205","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/art.10977","article-title":"Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis","volume":"48","author":"Hu","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.revmed.2023.11.006_bib0210","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/rheumatology\/40.10.1135","article-title":"Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis","volume":"40","author":"Sato","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.revmed.2023.11.006_bib0215","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E","article-title":"Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis","volume":"43","author":"Kuwana","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.006_bib0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"11","key":"10.1016\/j.revmed.2023.11.006_bib0225","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.revmed.2023.11.006_bib0115","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886632301250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886632301250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:47:10Z","timestamp":1759337230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886632301250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S024886632301250X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.11.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Des taux \u00e9lev\u00e9s d\u2019auto-anticorps anti-topo-isom\u00e9rase-1\u00a0sont associ\u00e9s \u00e0 l\u2019extension de la fibrose cutan\u00e9e et \u00e0 la progression vasculaire chez les patients atteints de scl\u00e9rodermie syst\u00e9mique","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}